In various hematopoietic malignancies including leukemia, lymphoma, and multiple myeloma, SV and their peptides were shown to modulate the NF-kB signaling pathway that is accountable for cancer cell growth and proliferation, and immune cell development and function, as shown in Table 4. This evidence concerns the gene NFKB1 and leukemia.